vs

Side-by-side financial comparison of CRYO CELL INTERNATIONAL INC (CCEL) and CPS TECHNOLOGIES CORP (CPSH). Click either name above to swap in a different company.

CPS TECHNOLOGIES CORP is the larger business by last-quarter revenue ($8.2M vs $7.8M, roughly 1.0× CRYO CELL INTERNATIONAL INC). CPS TECHNOLOGIES CORP runs the higher net margin — 0.2% vs -48.7%, a 48.8% gap on every dollar of revenue. On growth, CPS TECHNOLOGIES CORP posted the faster year-over-year revenue change (38.3% vs -2.3%). CRYO CELL INTERNATIONAL INC produced more free cash flow last quarter ($1.2M vs $-487.0K). Over the past eight quarters, CPS TECHNOLOGIES CORP's revenue compounded faster (17.8% CAGR vs -0.1%).

Cryo-Cell International, Inc. is a cord blood bank. It was founded by Dan Richard in 1989. Cryo-Cell International is the first private cord blood bank to separate and store stem cells. Cryo-Cell is headquartered outside of Tampa, in Oldsmar, Florida. In January 1997, the Company's stock began trading on the NASDAQ Small Cap market under symbol CCEL.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

CCEL vs CPSH — Head-to-Head

Bigger by revenue
CPSH
CPSH
1.0× larger
CPSH
$8.2M
$7.8M
CCEL
Growing faster (revenue YoY)
CPSH
CPSH
+40.6% gap
CPSH
38.3%
-2.3%
CCEL
Higher net margin
CPSH
CPSH
48.8% more per $
CPSH
0.2%
-48.7%
CCEL
More free cash flow
CCEL
CCEL
$1.7M more FCF
CCEL
$1.2M
$-487.0K
CPSH
Faster 2-yr revenue CAGR
CPSH
CPSH
Annualised
CPSH
17.8%
-0.1%
CCEL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCEL
CCEL
CPSH
CPSH
Revenue
$7.8M
$8.2M
Net Profit
$-3.8M
$12.6K
Gross Margin
77.9%
14.9%
Operating Margin
-50.6%
-1.2%
Net Margin
-48.7%
0.2%
Revenue YoY
-2.3%
38.3%
Net Profit YoY
-105.1%
101.3%
EPS (diluted)
$-0.46
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCEL
CCEL
CPSH
CPSH
Q4 25
$7.8M
$8.2M
Q3 25
$7.8M
$8.8M
Q2 25
$7.9M
$8.1M
Q1 25
$8.0M
$7.5M
Q4 24
$8.0M
$5.9M
Q3 24
$8.1M
$4.2M
Q2 24
$8.0M
$5.0M
Q1 24
$7.9M
$5.9M
Net Profit
CCEL
CCEL
CPSH
CPSH
Q4 25
$-3.8M
$12.6K
Q3 25
$749.4K
$208.0K
Q2 25
$355.8K
$103.8K
Q1 25
$282.9K
$96.0K
Q4 24
$-1.9M
$-995.2K
Q3 24
$1.1M
$-1.0M
Q2 24
$655.8K
$-954.3K
Q1 24
$556.2K
$-143.2K
Gross Margin
CCEL
CCEL
CPSH
CPSH
Q4 25
77.9%
14.9%
Q3 25
77.0%
17.1%
Q2 25
76.6%
16.5%
Q1 25
75.1%
16.4%
Q4 24
78.4%
-4.6%
Q3 24
73.6%
-12.3%
Q2 24
74.8%
-4.6%
Q1 24
73.7%
15.3%
Operating Margin
CCEL
CCEL
CPSH
CPSH
Q4 25
-50.6%
-1.2%
Q3 25
24.3%
3.1%
Q2 25
18.8%
1.7%
Q1 25
13.3%
1.7%
Q4 24
-1.5%
-22.2%
Q3 24
17.2%
-35.0%
Q2 24
17.3%
-26.1%
Q1 24
10.5%
-4.4%
Net Margin
CCEL
CCEL
CPSH
CPSH
Q4 25
-48.7%
0.2%
Q3 25
9.6%
2.4%
Q2 25
4.5%
1.3%
Q1 25
3.5%
1.3%
Q4 24
-23.2%
-16.8%
Q3 24
13.0%
-24.6%
Q2 24
8.2%
-19.0%
Q1 24
7.1%
-2.4%
EPS (diluted)
CCEL
CCEL
CPSH
CPSH
Q4 25
$-0.46
$0.00
Q3 25
$0.09
$0.01
Q2 25
$0.04
$0.01
Q1 25
$0.03
$0.01
Q4 24
$-0.23
$-0.07
Q3 24
$0.13
$-0.07
Q2 24
$0.08
$-0.07
Q1 24
$0.07
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCEL
CCEL
CPSH
CPSH
Cash + ST InvestmentsLiquidity on hand
$3.3M
$13.2M
Total DebtLower is stronger
$8.4M
Stockholders' EquityBook value
$-18.6M
$24.6M
Total Assets
$61.7M
$29.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCEL
CCEL
CPSH
CPSH
Q4 25
$3.3M
$13.2M
Q3 25
$3.2M
$4.3M
Q2 25
$4.4M
$3.4M
Q1 25
$3.5M
$3.0M
Q4 24
$3.5M
$4.3M
Q3 24
$2.1M
$5.7M
Q2 24
$1.5M
$7.1M
Q1 24
$979.6K
$8.7M
Total Debt
CCEL
CCEL
CPSH
CPSH
Q4 25
$8.4M
Q3 25
$8.4M
Q2 25
$8.4M
Q1 25
$8.5M
Q4 24
$8.5M
$8.1K
Q3 24
$8.5M
$20.1K
Q2 24
$8.5M
$31.9K
Q1 24
$8.6M
$43.5K
Stockholders' Equity
CCEL
CCEL
CPSH
CPSH
Q4 25
$-18.6M
$24.6M
Q3 25
$-14.8M
$15.1M
Q2 25
$-15.6M
$14.9M
Q1 25
$-14.7M
$14.7M
Q4 24
$-13.2M
$14.5M
Q3 24
$-9.6M
$15.4M
Q2 24
$-10.7M
$16.4M
Q1 24
$-10.3M
$17.3M
Total Assets
CCEL
CCEL
CPSH
CPSH
Q4 25
$61.7M
$29.5M
Q3 25
$63.2M
$20.4M
Q2 25
$64.4M
$19.4M
Q1 25
$64.4M
$19.2M
Q4 24
$64.7M
$18.9M
Q3 24
$62.9M
$19.2M
Q2 24
$62.6M
$20.1M
Q1 24
$61.7M
$21.2M
Debt / Equity
CCEL
CCEL
CPSH
CPSH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCEL
CCEL
CPSH
CPSH
Operating Cash FlowLast quarter
$1.3M
$243.6K
Free Cash FlowOCF − Capex
$1.2M
$-487.0K
FCF MarginFCF / Revenue
15.5%
-5.9%
Capex IntensityCapex / Revenue
0.9%
8.9%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$5.2M
$-479.6K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCEL
CCEL
CPSH
CPSH
Q4 25
$1.3M
$243.6K
Q3 25
$2.5M
$1.1M
Q2 25
$707.0K
$649.3K
Q1 25
$954.1K
$-1.3M
Q4 24
$2.2M
$-3.5M
Q3 24
$2.4M
$-1.2M
Q2 24
$1.8M
$-1.0M
Q1 24
$-356.9K
$128.9K
Free Cash Flow
CCEL
CCEL
CPSH
CPSH
Q4 25
$1.2M
$-487.0K
Q3 25
$2.5M
$876.8K
Q2 25
$644.6K
$476.4K
Q1 25
$892.0K
$-1.3M
Q4 24
$2.1M
$-4.5M
Q3 24
$2.3M
$-1.3M
Q2 24
$21.5K
$-1.6M
Q1 24
$-814.6K
$-134.5K
FCF Margin
CCEL
CCEL
CPSH
CPSH
Q4 25
15.5%
-5.9%
Q3 25
31.9%
10.0%
Q2 25
8.1%
5.9%
Q1 25
11.2%
-17.9%
Q4 24
26.8%
-75.3%
Q3 24
27.9%
-29.8%
Q2 24
0.3%
-31.8%
Q1 24
-10.4%
-2.3%
Capex Intensity
CCEL
CCEL
CPSH
CPSH
Q4 25
0.9%
8.9%
Q3 25
0.5%
2.0%
Q2 25
0.8%
2.1%
Q1 25
0.8%
1.2%
Q4 24
0.1%
16.8%
Q3 24
2.3%
1.9%
Q2 24
21.8%
11.0%
Q1 24
5.8%
4.5%
Cash Conversion
CCEL
CCEL
CPSH
CPSH
Q4 25
19.34×
Q3 25
3.38×
5.05×
Q2 25
1.99×
6.25×
Q1 25
3.37×
-13.05×
Q4 24
Q3 24
2.32×
Q2 24
2.70×
Q1 24
-0.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons